Free Newsletter

FEATURES >> 10 largest U.S. patent losses | 15 top blockbuster contenders | Emerging pharma jobs

Related Topics >> Genzyme

Genzyme: Should investors push sale or refocus?

January 19, 2010 — 11:13am ET | By Tracy Staton

Related Stories

Tools

A sale of Genzyme might book a quick gain for its stockholders, but Reuters posits that a smaller, more focused Genzyme might be the better outcome for investors. Report

SHARE
WITH:

More stories about Genzyme

Paid Research Reports

Trends in mHealth and Telemedicine
The Global Aesthetic Dermatology Market Outlook
Future Directions in Regenerative Medicine
Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline

More Research Reports >>